By : Business Editor
Jordan Daily – Dar Al Dawa Development & Investment Co., a leading Jordanian pharmaceutical manufacturer, reported a preliminary net profit of JOD 6.7 million for the fiscal year 2025, up from JOD 3.7 millionin 2024.
The results, reflect stronger profitability, improved margins, and a materially strengthened balance sheet, the company said in a disclosure sent to Amman Stock Exchange.
Chief Executive Officer Dr. Khaled Harb attributed the performance to disciplined execution, operational efficiency, and cross-functional collaboration.
“In an increasingly complex and rapidly evolving pharmaceutical industry, quality, agility, and sustainability are not slogans- they are the operating disciplines that consistently drive performance, resilience, and long-term value creation,” Dr. Harb said.
Harb had previously told Jordan Daily that the company’s success was also driven by restructuring initiatives, expansion into new markets, and ongoing investment in research and development, emphasizing the importance of strategic partnerships and innovation in sustaining growth.
Dar Al Dawa exports pharmaceuticals across the MENA region, including Saudi Arabia, the UAE, Algeria, Iraq, Morocco, and Tunisia, and has pursued partnerships with multinational companies to broaden its regional footprint.
The Amman-based company, listed on the Amman Stock Exchange under the ticker DADI, ranks among the top pharmaceutical firms in Jordan, with a growing market share and increasing international presence.
